DexTech is a Swedish research company specializing in drug development for urological oncology, primarily prostate cancer. Drug candidates are developed using CDC (carbohydrate-drug-conjugate) technology using a proprietary carbohydrate platform, GUA-Dex. The company conducts translational research and has a strong clinical foundation with specialist expertise in clinical oncology, pre-clinical research, and process development for drug manufacturing.
31 October, 2024
Bulletin from the Annual General Meeting
24 October, 2024
Interim report July 1- September 30, 2024
26 September, 2024
DexTech: Invitation to open Annual General Meeting and notice
DexTech’s patented technology platform, GuaDex, is used for our own medication development, but can also be licensed for other specific applications. The platform can be compared to building blocks, offering multiple ways of building new molecules.
Read moreDexTex has used GuaDex, its own technology platform, to develop four candidate medications: OsteoDex, SomaDex, CatDex and PSMA-Dx.
Read more